Ambrilia Biopharma Inc., a biopharmaceutical company developing innovative therapeutics in the fields of oncology and infectious diseases, announced today that it has received approval from the TSX to extend the term, from 5 to 10 years, of the 1 503 759 warrants to purchase common shares of Ambrilia at an exercice price of $0.56 per share granted to Investissement Quebec, and this, 10 business days following the date hereof. The warrants were issued to Investissement Quebec under the Biolevier program as previously announced on December 13, 2002. Such extension was already provided in the agreement with Investissement Quebec and was conditional upon changes being made to the rules of the TSX to allow for warrants to be granted for a term longer than five years. The new expiry date of the warrants is February 6, 2013.
